1 comparing insertion sites for central venous catheterization will help guide clinicians in their choice of sites. We were surprised, however, that the authors did not report the number of patients in each insertionsite group who were receiving positive-pressure ventilation. The increased positive end-expiratory pressure and large tidal volumes associated with mechanical ventilation can predispose a patient to the development of pneumothorax. Some evidence suggests that the risk of pneumothorax from subclavian-vein catheterization may be higher among patients receiving positive-pressure ventilation than among those not receiving it.
C o r r e s p o n d e n c e

Complications of Central Venous Catheterization
To the Editor: The results of the randomized trial by Parienti et al. (Sept. 24 issue) 1 comparing insertion sites for central venous catheterization will help guide clinicians in their choice of sites. We were surprised, however, that the authors did not report the number of patients in each insertionsite group who were receiving positive-pressure ventilation. The increased positive end-expiratory pressure and large tidal volumes associated with mechanical ventilation can predispose a patient to the development of pneumothorax. Some evidence suggests that the risk of pneumothorax from subclavian-vein catheterization may be higher among patients receiving positive-pressure ventilation than among those not receiving it. 2 Without knowing how the outcomes are stratified according to ventilation status, it is hard to fairly assess the true risk profile of subclavian-vein access.
The authors correctly observe that "the cumulative risk of infectious and thrombotic complications increases with increasing catheter exposure." We think the inference is worth stating more plainly: one means of preventing infectious complications from central venous catheterization is prompt removal of the catheter when it is no longer needed. Our institution is a typical Australian tertiary referral center. Local protocols for the insertion of central venous catheters mandate the following: skin preparation with topical chlorhexidine, chlorhexidine-impregnated catheters, and ultrasonographic guidance. 3 The rate of centralcatheter-associated bloodstream infections in local ICUs is 1.1 per 1000 catheter-days overall. Moreover, the rate of attributable iatrogenic pneumothorax in our ICU was 0 per 2221 insertions of central venous catheters from 2013 through 2015. We suggest that the findings of this week's letters 
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To the Editor: The 3SITES trial provides sitespecific complication rates after central venous catheterization and suggests the preferential use of the subclavian vein in critical illness. Not considered, however, are long-term complications, which might influence the choice of site, particularly in the subgroup of patients who are likely to require long-term dialysis.
Chronic central-vein stenosis is asymptomatic in many persons but leads to malfunction of surgically created arteriovenous fistulae in patients receiving dialysis, in whom it often recurs after venoplasty. Central-vein stenosis is particularly associated with catheters in the subclavian vein (as opposed to the internal jugular or femoral vein), 1,2 regardless of catheter size, even after short-term use. 3 This is of relevance to a growing proportion of patients: between 1996 and 2010, the percentage of critically ill patients who initiated dialysis during intensive care increased by a factor of almost 4, with up to a quarter of surviving patients remaining permanently dependent on dialysis. 4 The subclavian venous site may provide short-term benefits, but in those who may face permanent renal failure, this site has longerterm disadvantages that need consideration. 
To the Editor: In the trial reported by Parienti and colleagues, the authors conclude that subclavian catheterization was associated with a higher risk of pneumothorax than was jugular or femoral catheterization. We believe that this conclusion concerning the pneumothorax rate cannot be generalized to other ICUs for a number of reasons: both French and U.S. guidelines recommend the use of the ultrasonography-guided technique for all sites, but only 15% of the subclavian procedures in the present trial were performed with ultrasonographic guidance 1, 2 ; it cannot be ruled out that the ultrasonography-guided technique was preferentially chosen by operators in patients who presented with risk factors for pneumothorax (e.g., obesity or emphysema); and the incidence of pneumothorax in subclavian procedures reported here was 1.5%, whereas in studies using ultrasonography-guided subclavian procedures, the rate was between 0 and 0.2%, similar to the pneumothorax rate reported in the jugular site in the present trial. 3, 4 For all these reasons, the authors' conclusion that subclavian procedures are associated with an increased risk of pneumothorax pertains only to physicians using the nonrecommended landmark technique. To the Editor: Parienti et al. report catheterrelated infectious and thrombotic complications of central venous catheterization according to insertion site. They chose compression ultrasonography as the diagnostic standard for deepvein thrombosis (DVT). Although compression ultrasonography alone has efficacy that is similar to that of combined-method ultrasonography (color Doppler ultrasonography combined with compression ultrasonography) in diagnosing DVT in the legs, 1 this might not be the case for DVT in the arms. The vascular insertion site of subclavianvein catheterization is usually located beneath the clavicle, which makes it difficult for the site to be visualized or compressed with compression ultrasonography. Color Doppler ultrasonography has been shown to be more sensitive and accurate than compression ultrasonography in diagnosing DVT in the arms. 2 The American College of Chest Physicians guidelines also suggest initial evaluation with combined-method ultrasonography over other initial tests in patients with suspected DVT in the arms. 3 Using compression ultrasonography alone to diagnose subclavianvein thrombosis might lead to underestimation of the event rate. associated with the use of PEEP than with nonuse is difficult to assess, because the PEEP was turned off at the inserter's discretion during catheterization.
In response to Urbancic et al.: we used a rigorous definition of catheter-related bloodstream infection, 1 not the less accurate surveillance definition of central-catheter-associated bloodstream infection to which they refer. The former definition requires specific laboratory testing in order to unambiguously identify the catheter as the source of the bloodstream infection, whereas the latter definition indicates a bloodstream infection that occurred in the presence of a central catheter or within 48 hours after its removal, without any obvious other cause except the catheter. The low incidence of central-catheter-associated bloodstream infection that they report may relate to a different case mix or the use of chlorhexidinecoated catheters, which were not used in our trial. Given their low rate of pneumothorax, they could decrease further their incidence of central-catheter-associated bloodstream infection by adding the CDC and Australian and New Zealand Intensive Care Society guidelines recommendation "prefer the subclavian site" to their local protocol.
The risk of subclavian-vein stenosis 2 described by Corbett and Ashby has been associated with dialysis catheters. We excluded these devices.
Maizel and Slama may have misinterpreted the guidelines for catheterization 3 in the subclavian vein, which state, "We suggest that ultrasound dynamic guidance is of limited value for most operators to guide subclavian-vein catheterization in adult patients (and that landmark technique is used instead)." Our multicenter trial reflects current real-world practice in France, with ultrasonography used at the discretion of the operator.
Keng informs us about the sensitivity of compression ultrasonography to diagnose subclavian DVT. The rate of Doppler-defined subclavian DVT ranged from 2 cases per 107 catheters (1.9%) to 8 cases per 123 catheters (6.5%) in previous trials, 4 and we found a rate of 21 cases per 401 catheters (5.2%).
We agree with Bauer and colleagues that factors other than the insertion site can influence the risk of intravascular complications, but the site access was randomized. The CDC guidelines available when our trial was initiated 1 stated, "No comparison has been made between using chlorhexidine preparations with alcohol and povidone-iodine in alcohol to prepare clean skin. Unsolved issue." The results of the CLEAN trial
